INmune Bio and Quantum Computing Inc. Team Up to Run XPro Data Through a Quantum Optimizer

The partnership will use QCi’s Dirac-3S with AI and standard analytics to search for new disease uses and predictive biomarkers for XPro and to test whether the quantum approach adds practical value.

Overview

The companies announced a commercial collaboration to analyze INmune Bio’s preclinical and clinical XPro datasets using QCi’s Dirac-3S quantum optimizer alongside AI and conventional data methods.
Stage 1 will search for diseases that share XPro’s biology and for biomarkers that predict who responds, with a special emphasis on rare and pediatric indications that can allow smaller, faster trials.
XPro (XPro1595) is a dominant-negative TNF candidate that selectively blocks soluble TNF while sparing membrane-bound TNF, a profile intended to reduce neuroinflammation without broadly suppressing immune function.
QCi’s Dirac-3S is a room-temperature photonic entropy quantum optimizer rather than a general-purpose superconducting or trapped-ion computer, and the project will benchmark its results directly against standard statistical and machine-learning approaches.
The deal is QCi’s first pharma/biotech commercial engagement and includes options to expand work, but the effort is early and its value will hinge on whether quantum-enabled analyses produce actionable indications or biomarkers beyond conventional methods.